PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth

Cancer Letters

Volumn 338, Issue 2, 2013, Pages 282-291

  Su, Yansheng ^a,b   Yu, Liang ^a   Liu, Na ^c   Guo, Zhangyan ^d   Wang, Guodong ^a   Zheng, Jia ^a   Wei, Ming ^a   Wang, He ^a   Yang, An gang ^d   Qin, Weijun ^a   Wen, Weihong ^d  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Interventional Therapeutic Center   (China)

^c XI'AN JIAOTONG UNIVERSITY   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Notch1; Prostate cancer; Prostate specific membrane antigen; Single chain antibody; Small interfering RNA

Indexed keywords

FURIN; HYBRID PROTEIN; NOTCH1 RECEPTOR; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTAMINE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL PROLIFERATION; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CLEAVAGE; RNA INTERFERENCE; TUMOR GROWTH; XENOGRAFT;

MUS MUSCULUS;

NOTCH1; PROSTATE CANCER; PROSTATE-SPECIFIC MEMBRANE ANTIGEN; SINGLE-CHAIN ANTIBODY; SMALL INTERFERING RNA;

ANIMALS; ANTIBODY SPECIFICITY; ANTIGENS, SURFACE; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOCONJUGATES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTOR, NOTCH1; RNA, SMALL INTERFERING; SINGLE-CHAIN ANTIBODIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84881660772     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.05.035     Document Type: Article

References (47)

1. Carthew R.W., Sontheimer E.J. Origins and mechanisms of miRNAs and siRNAs. Cell 2009, 136:642-655.
2. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M., et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432:173-178.
3. de Fougerolles A., Vornlocher H.P., Maraganore J., Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discovery 2007, 6:443-453.
4. Zhao Z., Ma W., Zeng G., Qi D., Ou L., Liang Y. Small interference RNA-mediated silencing of prostate stem cell antigen attenuates growth, reduces migration and invasion of human prostate cancer PC-3M cells. Urol Oncol. 2011.
5. Sledz C.A., Holko M., de Veer M.J., Silverman R.H., Williams B.R. Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 2003, 5:834-839.
6. Jackson A.L., Bartz S.R., Schelter J., Kobayashi S.V., Burchard J., Mao M., et al. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 2003, 21:635-637.
7. Kariko K., Bhuyan P., Capodici J., Weissman D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J. Immunol. 2004, 172:6545-6549.
8. Dykxhoorn D.M., Lieberman J. The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Ann. Rev. Med. 2005, 56:401-423.
9. Ryther R.C., Flynt A.S., Phillips J.A., Patton J.G. SiRNA therapeutics: big potential from small RNAs. Gen. Ther. 2005, 12:5-11.
10. Leung R.K., Whittaker P.A. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol. Therm. 2005, 107:222-239.
11. Chiu S.J., Ueno N.T., Lee R.J. Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine. J. Control Release 2004, 97:357-369.
12. Guillem V.M., Tormo M., Revert F., Benet I., Garcia-Conde J., Crespo A., et al. Polyethyleneimine-based immunopolyplex for targeted gene transfer in human lymphoma cell lines. J. Gen. Med. 2002, 4:170-182.
13. Li S., Tan Y., Viroonchatapan E., Pitt B.R., Huang L. Targeted gene delivery to pulmonary endothelium by anti-PECAM antibody. Am. J. Physiol. Lung Cell Mol. Physiol. 2000, 278:L504-L511.
14. Chen S.Y., Zani C., Khouri Y., Marasco W.A. Design of a genetic immunotoxin to eliminate toxin immunogenicity. Gen. Ther. 1995, 2:116-123.
15. Li X., Stuckert P., Bosch I., Marks J.D., Marasco W.A. Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells. Cancer Gen. Therm. 2001, 8:555-565.
16. Song E., Zhu P., Lee S.K., Chowdhury D., Kussman S., Dykxhoorn D.M., et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 2005, 23:709-717.
17. Wen W.H., Liu J.Y., Qin W.J., Zhao J., Wang T., Jia L.T., et al. Targeted inhibition of HBV gene expression by single-chain antibody mediated small interfering RNA delivery. Hepatology 2007, 46:84-94.
18. Yao Y.D., Sun T.M., Huang S.Y., Dou S., Lin L., Chen J.N., et al. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. Sci. Transl. Med. 2012, 4:130ra48.
19. Ghosh A., Heston W.D. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J. Cell Biochem. 2004, 91:528-539.
20. Wolf P., Alt K., Wetterauer D., Buhler P., Gierschner D., Katzenwadel A., et al. Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer. J. Immunother 2010, 33:262-271.
21. Wang Z., Li Y., Banerjee S., Kong D., Ahmad A., Nogueira V., et al. Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways. J. Cell Biochem. 2010, 109:726-736.
22. Bin Hafeez B., Adhami V.M., Asim M., Siddiqui I.A., Bhat K.M., Zhong W., et al. Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clin, Cancer Res. 2009, 15:452-459.
23. Wang Z., Li Y., Ahmad A., Banerjee S., Azmi A.S., Kong D., et al. Down-regulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells. J. Cell Biochem. 2011, 112:78-88.
24. Hannon G.J. RNA Interference Nat. 2002, 418:244-251.
25. Wang X., Skelley L., Cade R., Sun Z. AAV delivery of mineralocorticoid receptor shRNA prevents progression of cold-induced hypertension and attenuates renal damage. Gen. Therm. 2006, 13:1097-1103.
26. Landen C.N., Chavez-Reyes A., Bucana C., Schmandt R., Deavers M.T., Lopez-Berestein G., et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005, 65:6910-6918.
27. Morrissey D.V., Lockridge J.A., Shaw L., Blanchard K., Jensen K., Breen W., et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 2005, 23:1002-1007.
28. Sorensen D.R., Leirdal M., Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J. Mol. Biol. 2003, 327:761-766.
29. Urban-Klein B., Werth S., Abuharbeid S., Czubayko F., Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gen. Therm. 2005, 12:461-466.
30. Vornlocher H.P. Antibody-directed cell-type-specific delivery of siRNA. Trends. Mol. Med. 2006, 12:1-3.
31. Guo S., Tschammer N., Mohammed S., Guo P. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. Hum. Gen. Therm. 2005, 16:1097-1109.
32. Schiffelers R.M., Ansari A., Xu J., Zhou Q., Tang Q., Storm G., et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 2004, 32:e149.
33. Williams B.R. Targeting specific cell types with silencing RNA. N Engl. J. Med. 2005, 353:1410-1411.
34. Pirollo K.F., Zon G., Rait A., Zhou Q., Yu W., Hogrefe R., et al. Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum Gen. Therm. 2006, 17:117-124.
35. Rossi J.J. Receptor-targeted siRNAs. Nat. Biotechnol. 2005, 23:682-684.
36. Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat. Rev. Mol. Cell Biol. 2002, 3:753-766.
37. Henrich S., Cameron A., Bourenkov G.P., Kiefersauer R., Huber R., Lindberg I., et al. The crystal structure of the proprotein processing proteinase furin explains its stringent specificity. Nat. Struct. Biol. 2003, 10:520-526.
38. Inocencio N.M., Moehring J.M., Moehring T.J. Furin activates pseudomonas exotoxin a by specific cleavage in vivo and in vitro. J. Biol. Chem. 1994, 269:31831-31835.
39. Chiron M.F., Fryling C.M., FitzGerald D. Furin-mediated cleavage of pseudomonas exotoxin-derived chimeric toxins. J. Biol. Chem. 1997, 272:31707-31711.
40. Stegmann T., Delfino J.M., Richards F.M., Helenius A. The HA2 subunit of influenza hemagglutinin inserts into the target membrane prior to fusion. J. Biol. Chem. 1991, 266:18404-18410.
41. Cross K.J., Langley W.A., Russell R.J., Skehel J.J., Steinhauer D.A. Composition and functions of the influenza fusion peptide. Protein Pept. Lett. 2009, 16:766-778.
42. Liou J.S., Liu B.R., Martin A.L., Huang Y.W., Chiang H.J., Lee H.J. Protein transduction in human cells is enhanced by cell-penetrating peptides fused with an endosomolytic HA2 sequence. Peptides 2012, 37:273-284.
43. Miele L. Notch signaling. Clin. Cancer Res. 2006, 12:1074-1079.
44. Miele L., Miao H., Nickoloff B.J. NOTCH signaling as a novel cancer therapeutic target. Curr. Cancer Drug Targets 2006, 6:313-323.
45. Zayzafoon M., Abdulkadir S.A., McDonald J.M. Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines. J. Biol. Chem. 2004, 279:3662-3670.
46. Lu P.Y., Xie F., Woodle M.C. In vivo application of RNA interference: from functional genomics to therapeutics. Adv. Genet. 2005, 54:117-142.
47. Hillier S.M., Maresca K.P., Femia F.J., Marquis J.C., Foss C.A., Nguyen N., et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009, 69:6932-6940.